Glenmark Pharmaceuticals, a global pharmaceutical company, today announced poster presentations of data from three clinical studies of Ryaltris, an investigational fixed-dose combination nasal spray for seasonal allergic rhinitis (SAR), at the AAAAI/WAO Joint Congress in Orlando, Florida.

Ryaltris (mometasone furoate (25 mcg) and olopatadine hydrochloride (665 mcg)), formerly GSP 301 Nasal Spray, is Glenmark's leading respiratory candidate with a New Drug Application filing anticipated in the first half of 2018

''Glenmark has a long history of expertise in respiratory diseases, and is committed to developing new and innovative treatments,'' said Fred Grossman, President and Chief Medical Officer at Glenmark Pharmaceuticals. ''We have studied the safety and efficacy of Ryaltris in more than a thousand patients over several years, and we are pleased to share these data at the AAAAI/WAO Joint Congress.''

Shares of the company gained Rs 4.6, or 0.84%, to trade at  Rs 555.30.  The total volume of shares traded  was  6,998 at the BSE (9.23 a.m., Tuesday).